Across the Nutraverse: P&G, Lallemand and Kirin on the acquisition trail
Procter & Gamble agreed to buy dietary supplement maker Thorne for $3.8 billion, with Thorne reported to exceed $500 million in annual revenue. Kirin Holdings agreed to acquire Jamieson Wellness for C$2.5 billion (US$1.78 billion). Lallemand completed its BIO-CAT Enzymes & Microbials acquisition, effective July 31, 2026, adding U.S. capacity.
How this was made
The 30-second read
Why it matters
For traders, the actionable elements are the disclosed transaction values, the stated strategic rationale, and the explicit closing dependency for P&G and Kirin, versus the already-effective completion for Lallemand.
Market read
This is a direct M&A catalyst set for three public acquirers, with near-term trading driven by deal premium expectations and closing/regulatory risk for the two pending transactions.
What to watch
Financing structure, antitrust/regulatory scrutiny, and how quickly added capacity translates into incremental revenue are not quantified here, which can dominate post-announcement price action.
Background
The article frames last week’s supplement-industry headlines as a wave of acquisitions, covering P&G and Kirin’s pending deals and Lallemand’s completed BIO-CAT purchase.
Ticker impact
P&G agreed to acquire Thorne for $3.8 billion, aiming to strengthen science-backed wellness and personalized health as the deal nears regulatory review.
Likely supportive for PG on deal premium expectations, but volatility around regulatory/closing risk.
The article provides a specific $3.8B acquisition price and states closing is later this year pending regulatory approvals, which typically drives initial repricing and then risk premium changes.
Market effects
Signals continued consolidation in dietary supplements and health ingredients, potentially increasing competitive pressure and bargaining power across R&D, manufacturing, and distribution.
North America remains a key target market, with deals aimed at scaling brands and distribution networks in the U.S. and Canada.
Cross-border transactions (Japan to North America, Canada to U.S.) highlight global supply-chain and fermentation/biotech capabilities as strategic assets.
Counterpoint
Large deal sizes can be value-destructive if integration costs, regulatory delays, or demand softness outweigh expected synergies, especially without disclosed financial terms for LND.
Key entities
- acquirerProcter & Gamble
Agreed to acquire Thorne for $3.8 billion, targeting science-backed wellness and personalized health.
- acquirerKirin Holdings
Agreed to acquire Jamieson Wellness for C$2.5 billion to expand Health Science into North America.
- acquirerLallemand
Completed acquisition of BIO-CAT Enzymes & Microbials effective July 31, 2026, adding U.S. production sites.
- targetThorne
Dietary supplement manufacturer being acquired by P&G; expected to close later this year pending regulatory approvals.
- targetJamieson Wellness
North America-focused wellness brand being acquired by Kirin; deal value C$2.5 billion.
